optimizing car-t outcomes in dlbcl: possible combination strategies & sequencing of agents
Published 1 year ago • 110 plays • Length 1:09Download video MP4
Download video MP3
Similar videos
-
2:48
outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
-
4:39
intermittent neutrophil recovery associated with improved car-t outcomes in r/r lbcl
-
1:58
patient-reported outcomes vs performance-based metrics: the effects of car-t therapy on cognition
-
3:07
the role of bridging and timing in car-t
-
2:53
safety and efficacy of allogenic car-t cell treatment
-
1:38
challenges of car-t therapy in the real-world setting
-
3:14
using machine learning to identify trajectories of hematotoxicity following car t-cell therapy
-
3:21
patient-reported outcomes with car t-cell therapy
-
4:49
patient-reported outcomes in car-t recipients
-
1:08
the benefits of car-t therapy in 2l over 3l in r/r dlbcl
-
3:15
outcomes and management of patients who develop covid-19 after cd19-targeted car-t therapy
-
2:11
improving treatment outcomes of car t-cell therapy
-
3:32
the risk of secondary malignancies following car t-cell therapy: current evidence
-
3:56
considerations and challenges of integrating car-t and transplantation in b-all
-
1:43
management of car-t related side effects
-
3:43
the future of car-t therapy
-
3:38
mechanisms of resistance to car-t in all: t-cell fitness, antigen loss and immunological rejection
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
2:00
tolerability of car-t therapies in clinical trials and in the real-world